Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.

Blüher M, Kurz I, Dannenmaier S, Dworak M.

World J Diabetes. 2012 Sep 15;3(9):161-9. doi: 10.4239/wjd.v3.i9.161.

2.

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Erratum in: Diabetes Obes Metab. 2009 Apr;11(4):405.

PMID:
19125777
3.

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G; Institution Investigators.

Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.

PMID:
22369287
4.

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Bosi E, Dotta F, Jia Y, Goodman M.

Diabetes Obes Metab. 2009 May;11(5):506-15. doi: 10.1111/j.1463-1326.2009.01040.x. Epub 2009 Mar 23.

PMID:
19320662
5.

Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.

Rosenstock J, Fitchet M.

Int J Clin Pract Suppl. 2008 Mar;(159):15-23. doi: 10.1111/j.1742-1241.2007.01692.x. Review.

PMID:
18269437
6.

Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.

Göke R, Bader G, Dworak M.

Diabetes Ther. 2014 Jun;5(1):183-91. doi: 10.1007/s13300-014-0060-4. Epub 2014 Mar 19.

7.

Efficacy and safety of a single-pill combination of vildagliptin and metformin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.

Odawara M, Yoshiki M, Sano M, Hamada I, Lukashevich V, Kothny W.

Diabetes Ther. 2015 Mar;6(1):17-27. doi: 10.1007/s13300-015-0099-x. Epub 2015 Feb 18.

9.

Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.

Ayvaz G, Keskin L, Akin F, Dokmetas HS, Tasan E, Ar IB, Uren E; GALATA Study Group.

Curr Med Res Opin. 2015 Apr;31(4):623-32. doi: 10.1185/03007995.2015.1019609. Epub 2015 Mar 16.

PMID:
25697921
10.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
11.

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Bolli G, Dotta F, Colin L, Minic B, Goodman M.

Diabetes Obes Metab. 2009 Jun;11(6):589-95. doi: 10.1111/j.1463-1326.2008.01023.x. Epub 2009 Apr 13.

PMID:
19515179
12.

Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.

Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W.

World J Diabetes. 2013 Aug 15;4(4):151-6. doi: 10.4239/wjd.v4.i4.151.

13.

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

Filozof C, Gautier JF.

Diabet Med. 2010 Mar;27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x. Erratum in: Diabet Med. 2013 May;30(5):632.

PMID:
20536495
14.

Translating science into clinical practice: focus on vildagliptin in combination with metformin.

Barnett AH.

Diabetes Obes Metab. 2009 May;11 Suppl 2:18-26. doi: 10.1111/j.1463-1326.2008.01030.x. Review.

PMID:
19385980
15.

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.

Odawara M, Hamada I, Suzuki M.

Diabetes Ther. 2014 Jun;5(1):169-81. doi: 10.1007/s13300-014-0059-x. Epub 2014 Mar 7.

16.

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S.

Horm Metab Res. 2008 Dec;40(12):892-5. doi: 10.1055/s-0028-1082334. Epub 2008 Aug 22.

PMID:
18726829
17.

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.

Bolli G, Dotta F, Rochotte E, Cohen SE.

Diabetes Obes Metab. 2008 Jan;10(1):82-90. Epub 2007 Nov 22.

PMID:
18034842
18.

Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.

Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, Andrews C, Barnett A.

Curr Med Res Opin. 2011 Jul;27(7):1367-74. doi: 10.1185/03007995.2011.579951. Epub 2011 May 16.

PMID:
21568833
19.

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ.

Diabetes Care. 2007 Apr;30(4):890-5. Epub 2007 Feb 2.

PMID:
17277036
Items per page

Supplemental Content

Write to the Help Desk